Madrid, January 23rd, 2024. The partners of Science & Innovation Link Office (SILO) and Ascendo Sanidad & Farma have announced today the business integration agreement. The result is the first healthcare and biotechnology innovation consultancy in Spain. The incorporation of Ascendo in SILO reinforces the area of life sciences and the socio-health sector, from which support and accompaniment is offered to all the agents in the sector: research centers, companies and public administrations.

Between the two firms, they have advised more than 50 pharmaceutical companies, 20 health technology companies, 100 biotechnology companies, several private hospital groups and venture capital funds. In the public sector, they have worked in all the Autonomous Communities, at the level of Regional Health and Social Services, with the Ministry of Health and the Carlos III Health Institute, as well as the main hospitals, institutes and biomedical research centers, universities and foundations, scientific societies, patient associations and other agents in the sector.

The culmination of the agreement comes in the context of a process of growth of the two firms, which have completed a decade of development in the field of specialized consulting in Spain, and which crystallizes in a reinforced project that adds more than 80 professionals and expects to have a turnover of 10 million euros in 2025.

With the incorporation of Ascendo, SILO takes another step forward in its consolidation as a reference consultancy firm in innovation projects and public-private collaboration, reinforcing the Health area.

The resulting firm will have a unique ability to offer comprehensive advice to its clients, combining services in strategy and operations, market access, corporate finance, R&D&I, search for funding, startup acceleration (, digitalization and legal advice. From these strengths it will be able to offer advanced solutions to address the main challenges of the healthcare system: sustainability, improving the quality and efficiency of care, digital transformation, the development of precision medicine and advanced therapies, value-based contracting or the promotion of biotech entrepreneurship, among others.

In the opinion of SILO’s CEO, Antonio López, “with this operation we reinforce our commitment to the sector, improving our capabilities in large transformation projects and public-private collaboration initiatives. These capabilities are especially necessary at this unique time of deployment of the Recovery, Transformation and Resilience Plan, which mobilizes the largest investments in healthcare innovation in history. Both firms have been working successfully on these projects and, after the transaction, we will be able to be even more ambitious in our desire to generate a transformational impact on the system.

For Manuel Carrasco, Managing Partner of Ascendo: “Together, both companies have more strength, ideas and tools to provide value and better support our clients, face challenges and continue to grow together. The agreement is an excellent opportunity to advance our proposal of innovative solutions and contribute more significantly to the improvement of quality and care processes. It reinforces our commitment to connect the growth opportunities of the different agents in the healthcare sector, contributing to the sustainable development and improvement of our healthcare and research and innovation system”.

Data attached photo: Antonio López, Cristina Garmendia (seated), Ángel Sanchez, Santiago Fernández, Lola Mateos (seated), Marta Salinas, Manuel Carrasco (seated) and Diego Moñux.

For BIOGA, it is a priority to promote intersectoral collaboration between entities and to power networking activities, both national and international. If you want to know more about us, please click the following link.